Curated News
By: NewsRamp Editorial Staff
August 11, 2026
NeuroOne Achieves ISO 13485 Certification, Paving Way for Global Expansion
TLDR
- NeuroOne's ISO 13485 certification unlocks international markets, offering a near-term revenue growth opportunity.
- ISO 13485 certification ensures NeuroOne's quality management system meets international standards for design, manufacturing, and distribution.
- NeuroOne's certification brings advanced neurological treatments closer to global patients, improving surgical outcomes and quality of life.
- NeuroOne's ISO 13485 milestone accelerates global expansion, with plans to partner with Zimmer Biomet for market entry.
Impact - Why it Matters
This certification is a critical step for NeuroOne as it enables the company to expand its market reach beyond the United States, potentially increasing revenue and growth opportunities. For patients and healthcare providers worldwide, this could mean access to innovative neurotechnology that improves surgical outcomes and quality of life. The certification also demonstrates NeuroOne's commitment to quality and compliance, which is essential for building trust with international partners and regulators. As the company plans to enter new markets with its distribution partner Zimmer Biomet, this milestone could accelerate the adoption of its products globally, ultimately benefiting patients suffering from neurological disorders.
Summary
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on surgical solutions for neurological disorders, has achieved ISO 13485-2016 certification, marking a significant milestone in its path to international commercialization. This certification, which is the international standard for quality management systems in the medical device industry, underscores the company's robust quality system and compliance capabilities, reducing the likelihood of product failures. The certification covers the design, development, manufacture, and distribution of electrosurgical generators, lesioning instruments, diagnostic neurophysiological instruments, anchor bolts, and cable assemblies used for recording, monitoring, stimulation, and radiofrequency lesioning of nervous system tissue. This achievement enables NeuroOne to pursue international marketing opportunities for its Evo® Cortical and Evo® sEEG Electrodes, and the OneRF® Brain Ablation System, although some geographies may have additional requirements before commercialization.
Dave Rosa, President and CEO of NeuroOne, expressed excitement about receiving the certification earlier than planned, stating that it 'opens the door for international revenue growth.' The company will collaborate with its distribution partner, Zimmer Biomet, to formulate a plan for entering markets with short-term paths to entry, while also exploring independent distributor partnerships for geographies held solely by NeuroOne. NeuroOne is dedicated to improving surgical care for patients with neurological disorders, offering minimally invasive, high-definition electrode technology with four FDA-cleared product families, including the Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System for the brain, and OneRF® Trigeminal Nerve Ablation System. These solutions aim to reduce hospitalizations, lower costs, and improve patient outcomes. The company is also engaged in R&D for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. For more information, visit nmtc1.com.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, NeuroOne Achieves ISO 13485 Certification, Paving Way for Global Expansion
